The University of Southampton
University of Southampton Institutional Repository

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study
Aromatase inhibitor (AI)-associated arthralgia limits adherence to therapy in breast cancer. The pathophysiology may involve vitamin D status. We wished to establish the optimal concentration of 25(OH)D that prevents or minimizes arthralgia. We used a prospective cohort of 290 women starting AI in whom baseline vitamin D was measured. All received daily vitamin D3 (800 IU) with calcium. Women with baseline 25(OH)D concentration <30 ng/ml also received 16,000 IU of D3 orally every 2 weeks. The primary outcome was incident or worsening joint pain derived from baseline and 3-month visual analogic scale (VAS) for joint pain. Regression models were used to analyse the association between vitamin D concentrations at 3 months and pain adjusting for age, BMI, season when the sample was drawn, aromatase inhibitor (exemestane vs. letrozole/anastrozole), prior tamoxifen therapy, baseline NTX, and previous fracture. 90% of women had a 25(OH)D <30 ng/ml at baseline. After supplementation (daily 800 IU and additional 16,000 IU every 2 weeks), 50% of them still failed to reach adequate concentrations at 3 months. In the whole cohort, there was an increase in joint pain (mean 1.16 points SD 2.66; P < 0.001) and the increase was significantly (P = 0.02) attenuated in those that reached concentrations of 25(OH)D of ?40 ng/ml, with a lower risk of incident arthralgia (OR 0.12 ** [0.03 to 0.40]). A target concentration of 40 ng/ml 25OHD may prevent development of AI arthralgia but higher loading doses are required to attain this level in women with deficiency at baseline.
0167-6806
869-878
Prieto-Alhambra, D.
19a5643f-5969-4c0e-b6a9-863fb9e9d1c7
Javaid, M.K.
51d3310b-032e-4c15-83ac-b878bce090f3
Servitja, S.
90681870-f898-42dd-8d1c-ffa8f200fe91
Arden, N.
23af958d-835c-4d79-be54-4bbe4c68077f
Martinez-Garcia, M.
d51564c3-2f9f-4824-9299-040958d68705
Diez-Perez, A.
19f89c53-003a-469c-92ac-69b0b979f3ec
Albanell, J.
128f57e7-b48e-4fb4-ac13-56f952418f78
Tusquets, X.
e29e4b31-1da7-4c90-a3fe-ef823a6ee249
Prieto-Alhambra, D.
19a5643f-5969-4c0e-b6a9-863fb9e9d1c7
Javaid, M.K.
51d3310b-032e-4c15-83ac-b878bce090f3
Servitja, S.
90681870-f898-42dd-8d1c-ffa8f200fe91
Arden, N.
23af958d-835c-4d79-be54-4bbe4c68077f
Martinez-Garcia, M.
d51564c3-2f9f-4824-9299-040958d68705
Diez-Perez, A.
19f89c53-003a-469c-92ac-69b0b979f3ec
Albanell, J.
128f57e7-b48e-4fb4-ac13-56f952418f78
Tusquets, X.
e29e4b31-1da7-4c90-a3fe-ef823a6ee249

Prieto-Alhambra, D., Javaid, M.K., Servitja, S., Arden, N., Martinez-Garcia, M., Diez-Perez, A., Albanell, J. and Tusquets, X. (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Research and Treatment, 125 (3), 869-878. (doi:10.1007/s10549-010-1075-9). (PMID:20665105)

Record type: Article

Abstract

Aromatase inhibitor (AI)-associated arthralgia limits adherence to therapy in breast cancer. The pathophysiology may involve vitamin D status. We wished to establish the optimal concentration of 25(OH)D that prevents or minimizes arthralgia. We used a prospective cohort of 290 women starting AI in whom baseline vitamin D was measured. All received daily vitamin D3 (800 IU) with calcium. Women with baseline 25(OH)D concentration <30 ng/ml also received 16,000 IU of D3 orally every 2 weeks. The primary outcome was incident or worsening joint pain derived from baseline and 3-month visual analogic scale (VAS) for joint pain. Regression models were used to analyse the association between vitamin D concentrations at 3 months and pain adjusting for age, BMI, season when the sample was drawn, aromatase inhibitor (exemestane vs. letrozole/anastrozole), prior tamoxifen therapy, baseline NTX, and previous fracture. 90% of women had a 25(OH)D <30 ng/ml at baseline. After supplementation (daily 800 IU and additional 16,000 IU every 2 weeks), 50% of them still failed to reach adequate concentrations at 3 months. In the whole cohort, there was an increase in joint pain (mean 1.16 points SD 2.66; P < 0.001) and the increase was significantly (P = 0.02) attenuated in those that reached concentrations of 25(OH)D of ?40 ng/ml, with a lower risk of incident arthralgia (OR 0.12 ** [0.03 to 0.40]). A target concentration of 40 ng/ml 25OHD may prevent development of AI arthralgia but higher loading doses are required to attain this level in women with deficiency at baseline.

This record has no associated files available for download.

More information

Published date: February 2011

Identifiers

Local EPrints ID: 172881
URI: http://eprints.soton.ac.uk/id/eprint/172881
ISSN: 0167-6806
PURE UUID: 83646f53-ecf5-45e5-9c04-9c01c9a43bf2

Catalogue record

Date deposited: 31 Jan 2011 15:02
Last modified: 14 Mar 2024 02:30

Export record

Altmetrics

Contributors

Author: D. Prieto-Alhambra
Author: M.K. Javaid
Author: S. Servitja
Author: N. Arden
Author: M. Martinez-Garcia
Author: A. Diez-Perez
Author: J. Albanell
Author: X. Tusquets

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×